Our lead product candidate, Trans sodium crocetinate (TSC), is a first-in-class, small molecule therapeutic with a novel mechanism-of-action that enhances the diffusion of oxygen to hypoxic tissues.
TSC would be the first therapy specifically designed to enhance the oxygen diffusion process, thereby supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points. In animal models, this diffusion-enhancing mechanism-of-action has been observed to affect hypoxic tissue preferentially while avoiding excessive oxygen-related tissue toxicity, also known as hyperoxia.
TSC has been observed to be safe and well-tolerated at most doses tested in over 200 subjects included to-date in our clinical studies.
The company’s second pipeline asset, DFN-529, is a novel, allosteric PI3K/Akt/mTOR pathway inhibitor. Two Phase 1 clinical trials have been completed evaluating DFN-529 in age-related macular degeneration and preclinical studies have been performed in preclinical models of glioblastoma multiforme (GBM).